Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | UTHR |
---|---|---|
09:32 ET | 1916 | 358.2 |
09:38 ET | 699 | 359.93 |
09:41 ET | 1000 | 359.66 |
09:48 ET | 200 | 359.89 |
09:52 ET | 300 | 359.19 |
09:54 ET | 312 | 359 |
09:59 ET | 541 | 358.83 |
10:01 ET | 288 | 358.49 |
10:03 ET | 100 | 359.0821 |
10:06 ET | 521 | 359.39 |
10:10 ET | 750 | 360.3218 |
10:12 ET | 300 | 359.88 |
10:14 ET | 900 | 359.3 |
10:15 ET | 103 | 359.97 |
10:17 ET | 200 | 359.1 |
10:19 ET | 100 | 359.7199 |
10:21 ET | 200 | 359.2117 |
10:24 ET | 100 | 359.61 |
10:28 ET | 1005 | 359.82 |
10:30 ET | 200 | 359.98 |
10:32 ET | 600 | 359.92 |
10:33 ET | 400 | 358.96 |
10:35 ET | 700 | 359.28 |
10:44 ET | 100 | 358.55 |
10:46 ET | 200 | 358.48 |
10:48 ET | 393 | 358.87 |
10:50 ET | 100 | 358.33 |
10:51 ET | 100 | 358.9 |
10:53 ET | 200 | 358.54 |
10:55 ET | 200 | 358.335 |
10:57 ET | 600 | 357.92 |
11:00 ET | 374 | 358.01 |
11:04 ET | 200 | 357.7 |
11:08 ET | 200 | 358.45 |
11:09 ET | 200 | 358.67 |
11:11 ET | 300 | 359.06 |
11:15 ET | 100 | 358.87 |
11:20 ET | 100 | 359 |
11:22 ET | 329 | 358.2 |
11:29 ET | 100 | 358.56 |
11:31 ET | 100 | 358.65 |
11:33 ET | 1200 | 358.04 |
11:36 ET | 3000 | 357.8 |
11:38 ET | 300 | 357.965 |
11:40 ET | 100 | 357.68 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
United Therapeutics Corp | 15.9B | 16.4x | +8.22% |
Biomarin Pharmaceutical Inc | 13.4B | 53.1x | --- |
Exact Sciences Corp | 12.6B | -69.7x | --- |
Neurocrine Biosciences Inc | 11.7B | 34.9x | +62.04% |
Qiagen NV | 10.1B | 143.8x | +12.66% |
Beigene Ltd | 23.3B | -43.7x | --- |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9B |
---|---|
Revenue (TTM) | $2.6B |
Shares Outstanding | 44.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $21.75 |
Book Value | $127.23 |
P/E Ratio | 16.4x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | 14.1x |
Operating Margin | 48.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.